[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prame-positive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prame-positive":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100604947",false,"NCT07156136","Study of IMC-P115C in Advanced PRAME-Positive Cancers","A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* HLA-A\\*02:01-positive\n* Meeting PRAME-positive tumor testing requirements\n* Metastatic or unresectable solid tumors\n* Have received (or be receiving), relapsed from, be refractory to or intolerant of all therapies\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control\n\nExclusion Criteria:\n\n* Symptomatic or untreated central nervous system metastasis\n* Bowel obstruction, perforation, or fistula formation within 3 months prior to the planned first dose of study treatment\n* Ongoing ascites or effusion requiring recent drainages\n* Significant ongoing toxicity from prior anticancer treatment\n* Out-of-range laboratory values\n* Clinically significant lung, heart, or autoimmune disease\n* Ongoing requirement for immunosuppressive treatment\n* Significant secondary malignancy\n* Hypersensitivity to study drug or excipients\n* Pregnant or lactating","ALL","18 Years",{"count":18,"type":19},140,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.",[25,26,27],"PRAME Positive","Cancer","HLA-A*02:01-positive",[29],"PRAME","RECRUITING","2026-02-23",{"date":33,"type":34},"2026-02-25","ACTUAL",{"date":36,"type":34},"2024-11-07",{"date":38,"type":19},"2029-08-30",{"name":40,"class":41},"Immunocore Ltd","INDUSTRY",13,""]